# Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer

> **NCT07552181** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yuan Yuan** · enrollment: 50 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer
- TNBC
- Early Stage Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Live biotherapeutic product: MO-03 1 capsule PO BID

## Key facts

- **NCT ID:** NCT07552181
- **Lead sponsor:** Yuan Yuan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2035-09
- **Final completion:** 2035-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07552181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07552181, "Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07552181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*